Back to News
Market Impact: 0.2
Beactica Therapeutics initiates IND-enabling studies for BEA-17, a first-in-class LSD1-CoREST degrader for glioblastoma
Source: PR Newswire
Healthcare & BiotechTechnology & Innovation
Beactica Therapeutics initiated IND-enabling studies for BEA-17, its wholly owned first-in-class oral degrader targeting the epigenetic regulators LSD1 and CoREST. The development milestone advances the Swedish precision-medicine company's preclinical oncology pipeline toward a potential IND filing, though no clinical data, financial details, or regulatory timeline were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- Wall Street’s Nasdaq hits all-time high as AI frenzy gathers pace
- Data-Center Bet Makes ESDS One of India’s Best New Listings
- Asia stocks ride tech wave higher, oil stays subdued
- U.S. regulators rush to write crypto rulebook after Clarity Act stalls in Senate
- Meta is breaking out after introducing Muse AI agent. Where the stock is going, according to the charts
- Anthropic in talks to lease 1 gigawatt from Stream Data Centers- The Information
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Automating Financial Model Updates: A Source-Controlled Workflow
- Weekly Update: Live Event Center, In-App Documents, and Faster Transcripts